Clinical Trial Update: Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus [Phase 2]

View source ↗

Summary

Phase 2 study evaluating TC-6987 as monotherapy for Type 2 diabetes mellitus, focusing on glycemic control, safety, and tolerability; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• TC-6987

Snippet

Sponsor: Targacept Inc. | Conditions: Type 2 Diabetes Mellitus | Phase 2 | Status: COMPLETED